Vaccines Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit & Conjugate Vaccines, and Others), Technology [Recombinant Vaccines, mRNA Vaccines, Cell-Based Vaccines, Virus-Like Particles (VLPs), and Others], Application (Human Papillomavirus, Cancer, MMR, DPT, and Others), Route of Administration (Oral, Injectable, and Nasal), Age (Pediatric Vaccine and Adult Vaccine), End User (Healthcare Facilities, Vaccination Programs and Centers, and Others),(and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
The vaccines market is expected to grow from US$ 135.28 billion in 2022 to US$ 216.30 billion by 2030; it is expected to grow at a CAGR of 6.0% from 2022 to 2030. Rising prevalence of infectious diseases and an increase for uptake of vaccines amid the COVID-19 pandemic are a few factors driving the vaccines market growth.
A vaccine is a biological preparation that provides active acquired immunity to a particular infectious or malignant disease. A vaccine typically preparation contains an agent responsible for resembling a disease-causing microorganism and is often made from a weakened or killed form of the microbe, toxin, or one of its surface proteins. Vaccines can be prophylactic or therapeutic, offering immunity.
Market Opportunity
Therapeutic Vaccine Development
Traditional vaccines stimulate the production of antibodies and immune proteins that target specific pathogens like viruses and bacteria. Likewise, therapeutic vaccines stimulate the immune system to target cancer cells and control the progression of chronic infections like HIV. Further, therapeutic vaccines typically stimulate the recipient's immune system to slow or stop chronic disease progression or target cancer cells. Further, therapeutic vaccines for the treatment of noninfectious diseases encompass a wide variety of possible formulations, antigens, and mechanism of action. Therefore, therapeutic vaccines development will provide lucrative market opportunity for the forecast period 2022-2030.
Examples of Therapeutic Vaccines in Development
Indication Development Phase
Ovarian Cancer Phase 1
Multiple Myeloma Phase 1
Type 1 Diabetes Preclinical
Acute Myelogenous Leukemia 3
Mesothelioma 2
Source: TheInsight Partners Analysis
Market Insights
Rising Infectious Diseases
According to the Connecticut Department of Public Health report 2020, below are the infectious diseases recorded in 2020 in Connecticut.
Reported Cases of Connecticut Reportable Diseases in 2020
Disease Total
Hepatitis A 15
Influenza 98
Malaria 4
Tuberculosis 54
SARS-CoV-2 2,00,379
Source: TheInsight Partners Analysis
Additionally, the below table reveals notable infectious disease by the Center for Health Protection report in 2020:
Notable Infectious Disease
Disease Total
SARS-CoV-2 8847
Chickenpox 1987
Community-associated methicillin-resistant Staphylococcus aureus infection 813
Dengue Fever 22
Tuberculosis 3656
Source: TheInsight Partners Analysis
Among all the infectious diseases, SARS-CoV-2 was all time high during 2020 to 2022 period where other uptake of vaccines including Dengue, Chickenpox, Tuberculosis, and others were low. However, SARS-CoV-2 vaccines uptake was all time high due to rising cases globally. According to the Public Health England report published in 2021, 12-month UK coverage for DTaP/IPV/Hib/HepB3 vaccination increased by 0.1% to 92.2% and Rotavirus by 0.3% to 90.6%. However, MenB2 decreased by 0.1, accounting for 92.3% compared to the previous year. Also, the NHS England report reveals that, in December 2022, a total of 88.9 of all adult care home residents had been vaccinated with a COVID-19 booster dose. Therefore, rising prevalence of infectious diseases, demand for vaccination is high resulting in overall market growth for the forecast period 2022-2030.
Type-Based Insights
Based on type, the vaccines market is segmented as live attenuated vaccines, inactivated vaccines, toxoid vaccines, subunit & conjugate vaccines, and others. The live attenuated vaccines segment held the largest market share in 2022. Live attenuated vaccines are very effective vaccines used in the prevention of a variety of diseases, including influenza, chickenpox, measles, polio, and tuberculosis. As per the World Health Organization (WHO) report, there are around a billion cases of seasonal influenza, including 5 million cases of severe illness. Also, it causes around 290,000 to 650,000 respiratory deaths annually. Therefore, live-attenuated influenza vaccine (LAIV) proves advantageous to combat the infection among the population. For example, LAIV can provide upto 90% protection among adults under 65 years of age and upto 40% of adults over 65. The aforementioned factors are responsible for influential segment growth for the forecast period 2022-2030.
Based on application, the vaccines market is segregated into Human Papillomavirus (HPV), cancer, MMR, DPT, and others. The HPV segment held the largest market share in 2022. According to the WHO report, HPV is highly prevalent among women in Sub-Saharan Africa (24%), followed by Latin America and the Caribbean (16%), Eastern Europe (14%), and South-East Asia (14%). Also, 625,600 women and 694,000 men have HPV-related cancer annually globally. Also, in 2020, cervical cancer accounted for 93% of HPV-related cancers among women. Therefore, there is a high demand for HPV vaccines among the population due to rising prevalent cases, as these vaccines protect against genital warts and most cases of cervical cancer. Also, HPV vaccines are highly approved by the US Food and Drug Administration (USFDA). 'GARDASIL 9' is one such example of an HPV vaccine approved by the US FDA. The aforementioned factors are responsible for influential segment growth for the forecast period 2022-2030.
Route of Administration-Based Insights
In terms of route of administration, the vaccines market is categorized as oral, nasal, and injectable. The injectable segment held a larger share of the market in 2022. The most common route of vaccine administration is through the injectable route, as administering a vaccine through a subcutaneous or intradermal route may cause local irritation, skin discoloration, inflammation, and many more.
Further, the CDC report reveals that DTaP, DT, HepA, HepB, Hib, HPV, IIV4, RIV4, ccIIV4, IPV*†, MenACWY, MenB, MMR‡ , PCV13, PPSV23*†, RZV, Td, Tdap, TT, VAR† are common vaccines administered through the injectable route of administration. Varied vaccines administered through injectable routes act as a standalone factor responsible for influential segment growth for the forecast period 2022-2030.
A vaccine is a biological preparation that provides active acquired immunity to a particular infectious or malignant disease. A vaccine typically preparation contains an agent responsible for resembling a disease-causing microorganism and is often made from a weakened or killed form of the microbe, toxin, or one of its surface proteins. Vaccines can be prophylactic or therapeutic, offering immunity.
Market Opportunity
Therapeutic Vaccine Development
Traditional vaccines stimulate the production of antibodies and immune proteins that target specific pathogens like viruses and bacteria. Likewise, therapeutic vaccines stimulate the immune system to target cancer cells and control the progression of chronic infections like HIV. Further, therapeutic vaccines typically stimulate the recipient's immune system to slow or stop chronic disease progression or target cancer cells. Further, therapeutic vaccines for the treatment of noninfectious diseases encompass a wide variety of possible formulations, antigens, and mechanism of action. Therefore, therapeutic vaccines development will provide lucrative market opportunity for the forecast period 2022-2030.
Examples of Therapeutic Vaccines in Development
Indication Development Phase
Ovarian Cancer Phase 1
Multiple Myeloma Phase 1
Type 1 Diabetes Preclinical
Acute Myelogenous Leukemia 3
Mesothelioma 2
Source: TheInsight Partners Analysis
Market Insights
Rising Infectious Diseases
According to the Connecticut Department of Public Health report 2020, below are the infectious diseases recorded in 2020 in Connecticut.
Reported Cases of Connecticut Reportable Diseases in 2020
Disease Total
Hepatitis A 15
Influenza 98
Malaria 4
Tuberculosis 54
SARS-CoV-2 2,00,379
Source: TheInsight Partners Analysis
Additionally, the below table reveals notable infectious disease by the Center for Health Protection report in 2020:
Notable Infectious Disease
Disease Total
SARS-CoV-2 8847
Chickenpox 1987
Community-associated methicillin-resistant Staphylococcus aureus infection 813
Dengue Fever 22
Tuberculosis 3656
Source: TheInsight Partners Analysis
Among all the infectious diseases, SARS-CoV-2 was all time high during 2020 to 2022 period where other uptake of vaccines including Dengue, Chickenpox, Tuberculosis, and others were low. However, SARS-CoV-2 vaccines uptake was all time high due to rising cases globally. According to the Public Health England report published in 2021, 12-month UK coverage for DTaP/IPV/Hib/HepB3 vaccination increased by 0.1% to 92.2% and Rotavirus by 0.3% to 90.6%. However, MenB2 decreased by 0.1, accounting for 92.3% compared to the previous year. Also, the NHS England report reveals that, in December 2022, a total of 88.9 of all adult care home residents had been vaccinated with a COVID-19 booster dose. Therefore, rising prevalence of infectious diseases, demand for vaccination is high resulting in overall market growth for the forecast period 2022-2030.
Type-Based Insights
Based on type, the vaccines market is segmented as live attenuated vaccines, inactivated vaccines, toxoid vaccines, subunit & conjugate vaccines, and others. The live attenuated vaccines segment held the largest market share in 2022. Live attenuated vaccines are very effective vaccines used in the prevention of a variety of diseases, including influenza, chickenpox, measles, polio, and tuberculosis. As per the World Health Organization (WHO) report, there are around a billion cases of seasonal influenza, including 5 million cases of severe illness. Also, it causes around 290,000 to 650,000 respiratory deaths annually. Therefore, live-attenuated influenza vaccine (LAIV) proves advantageous to combat the infection among the population. For example, LAIV can provide upto 90% protection among adults under 65 years of age and upto 40% of adults over 65. The aforementioned factors are responsible for influential segment growth for the forecast period 2022-2030.
Based on application, the vaccines market is segregated into Human Papillomavirus (HPV), cancer, MMR, DPT, and others. The HPV segment held the largest market share in 2022. According to the WHO report, HPV is highly prevalent among women in Sub-Saharan Africa (24%), followed by Latin America and the Caribbean (16%), Eastern Europe (14%), and South-East Asia (14%). Also, 625,600 women and 694,000 men have HPV-related cancer annually globally. Also, in 2020, cervical cancer accounted for 93% of HPV-related cancers among women. Therefore, there is a high demand for HPV vaccines among the population due to rising prevalent cases, as these vaccines protect against genital warts and most cases of cervical cancer. Also, HPV vaccines are highly approved by the US Food and Drug Administration (USFDA). 'GARDASIL 9' is one such example of an HPV vaccine approved by the US FDA. The aforementioned factors are responsible for influential segment growth for the forecast period 2022-2030.
Route of Administration-Based Insights
In terms of route of administration, the vaccines market is categorized as oral, nasal, and injectable. The injectable segment held a larger share of the market in 2022. The most common route of vaccine administration is through the injectable route, as administering a vaccine through a subcutaneous or intradermal route may cause local irritation, skin discoloration, inflammation, and many more.
Further, the CDC report reveals that DTaP, DT, HepA, HepB, Hib, HPV, IIV4, RIV4, ccIIV4, IPV*†, MenACWY, MenB, MMR‡ , PCV13, PPSV23*†, RZV, Td, Tdap, TT, VAR† are common vaccines administered through the injectable route of administration. Varied vaccines administered through injectable routes act as a standalone factor responsible for influential segment growth for the forecast period 2022-2030.
1. INTRODUCTION
1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness Analysis
3. RESEARCH METHODOLOGY
4. VACCINES MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.3.1 List of Vendors in the Value Chain
5. VACCINES MARKET - KEY MARKET DYNAMICS
5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints
6. VACCINES MARKET - GLOBAL MARKET ANALYSIS
6.1 Vaccines - Global Market Overview
6.2 Vaccines - Global Market and Forecast to 2030
7. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY TYPE, 2020-2030
7.1 Overview
7.2 Live Attenuated Vaccines
7.3 Inactivated Vaccines
7.4 Toxoid Vaccines
7.5 Subunit and Conjugate Vaccines
7.6 Others
8. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY TECHNOLOGY, 2020-2030
8.1 Overview
8.2 Recombinant Vaccines
8.3 mRNA Vaccines
8.4 Cell-Based Vaccines
8.5 Virus-Like Particles (VLPs)
8.6 Others
9. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY APPLICATION, 2020-2030
9.1 Overview
9.2 Human Papillomavirus (HPV)
9.3 Cancer
9.4 Measles, Mumps, Rubella (MMR)
9.5 Diptheria, Pertusis, Tetanus (DPT)
9.6 Others
10. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY ROUTE OF ADMINISTRATION, 2020-2030
10.1 Overview
10.2 Oral
10.3 Injectable
10.4 Nasal
11. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY AGE, 2020-2030
11.1 Overview
11.2 Pediatric
11.3 Adult
12. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY END USER, 2020-2030
12.1 Overview
12.2 Healthcare Facilities (HCF)
12.3 Vaccination Centers and Programs
12.4 Others
13. VACCINES MARKET - REVENUE ANALYSIS (USD MILLION), 2020-2030 – GEOGRAPHICAL ANALYSIS
13.1 North America
13.1.1 North America Vaccines Market Overview
13.1.2 North America Vaccines Market Revenue and Forecasts to 2030
13.1.3 North America Vaccines Market Revenue and Forecasts and Analysis - By Type
13.1.4 North America Vaccines Market Revenue and Forecasts and Analysis - By Technology
13.1.5 North America Vaccines Market Revenue and Forecasts and Analysis - By Application
13.1.6 North America Vaccines Market Revenue and Forecasts and Analysis - By Route of Administration
13.1.7 North America Vaccines Market Revenue and Forecasts and Analysis - By Age
13.1.8 North America Vaccines Market Revenue and Forecasts and Analysis - By End User
13.1.9 North America Vaccines Market Revenue and Forecasts and Analysis - By Countries
13.1.9.1 United States Vaccines Market
13.1.9.1.1 United States Vaccines Market, by Type
13.1.9.1.2 United States Vaccines Market, by Technology
13.1.9.1.3 United States Vaccines Market, by Application
13.1.9.1.4 United States Vaccines Market, by Route of Administration
13.1.9.1.5 United States Vaccines Market, by Age
13.1.9.1.6 United States Vaccines Market, by End User
13.1.9.2 Canada Vaccines Market
13.1.9.2.1 Canada Vaccines Market, by Type
13.1.9.2.2 Canada Vaccines Market, by Technology
13.1.9.2.3 Canada Vaccines Market, by Application
13.1.9.2.4 Canada Vaccines Market, by Route of Administration
13.1.9.2.5 Canada Vaccines Market, by Age
13.1.9.2.6 Canada Vaccines Market, by End User
13.1.9.3 Mexico Vaccines Market
13.1.9.3.1 Mexico Vaccines Market, by Type
13.1.9.3.2 Mexico Vaccines Market, by Technology
13.1.9.3.3 Mexico Vaccines Market, by Application
13.1.9.3.4 Mexico Vaccines Market, by Route of Administration
13.1.9.3.5 Mexico Vaccines Market, by Age
13.1.9.3.6 Mexico Vaccines Market, by End User
Note - Similar analysis would be provided for below mentioned regions/countries
13.2 Europe
13.2.1 Germany
13.2.2 France
13.2.3 Italy
13.2.4 Spain
13.2.5 United Kingdom
13.2.6 Rest of Europe
13.3 Asia-Pacific
13.3.1 Australia
13.3.2 China
13.3.3 India
13.3.4 Japan
13.3.5 South Korea
13.3.6 Rest of Asia-Pacific
13.4 Middle East and Africa
13.4.1 South Africa
13.4.2 Saudi Arabia
13.4.3 U.A.E
13.4.4 Rest of Middle East and Africa
13.5 South and Central America
13.5.1 Brazil
13.5.2 Argentina
13.5.3 Rest of South and Central America
14. PRE AND POST COVID-19 IMPACT
15. INDUSTRY LANDSCAPE
15.1 Mergers and Acquisitions
15.2 Agreements, Collaborations, Joint Ventures
15.3 New Product Launches
15.4 Expansions and Other Strategic Developments
16. COMPETITIVE LANDSCAPE
16.1 Heat Map Analysis by Key Players
16.2 Company Positioning and Concentration
17. VACCINES MARKET - KEY COMPANY PROFILES
17.1 GSK
17.1.1 Key Facts
17.1.2 Business Description
17.1.3 Products and Services
17.1.4 Financial Overview
17.1.5 SWOT Analysis
17.1.6 Key Developments
Note - Similar information would be provided for below list of companies
17.2 Pfizer
17.3 Sanofi
17.4 Merck
17.5 Serum Institute of India (SII)
17.6 AstraZeneca
17.7 BioNTech
17.8 Biological E
17.9 Sinovac
17.10 Sinopharm
17.11 Bharat Biotech
18. APPENDIX
18.1 Glossary
18.2 About The Insight Partners
18.3 Market Intelligence Cloud
1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness Analysis
3. RESEARCH METHODOLOGY
4. VACCINES MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.3.1 List of Vendors in the Value Chain
5. VACCINES MARKET - KEY MARKET DYNAMICS
5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints
6. VACCINES MARKET - GLOBAL MARKET ANALYSIS
6.1 Vaccines - Global Market Overview
6.2 Vaccines - Global Market and Forecast to 2030
7. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY TYPE, 2020-2030
7.1 Overview
7.2 Live Attenuated Vaccines
7.3 Inactivated Vaccines
7.4 Toxoid Vaccines
7.5 Subunit and Conjugate Vaccines
7.6 Others
8. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY TECHNOLOGY, 2020-2030
8.1 Overview
8.2 Recombinant Vaccines
8.3 mRNA Vaccines
8.4 Cell-Based Vaccines
8.5 Virus-Like Particles (VLPs)
8.6 Others
9. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY APPLICATION, 2020-2030
9.1 Overview
9.2 Human Papillomavirus (HPV)
9.3 Cancer
9.4 Measles, Mumps, Rubella (MMR)
9.5 Diptheria, Pertusis, Tetanus (DPT)
9.6 Others
10. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY ROUTE OF ADMINISTRATION, 2020-2030
10.1 Overview
10.2 Oral
10.3 Injectable
10.4 Nasal
11. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY AGE, 2020-2030
11.1 Overview
11.2 Pediatric
11.3 Adult
12. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY END USER, 2020-2030
12.1 Overview
12.2 Healthcare Facilities (HCF)
12.3 Vaccination Centers and Programs
12.4 Others
13. VACCINES MARKET - REVENUE ANALYSIS (USD MILLION), 2020-2030 – GEOGRAPHICAL ANALYSIS
13.1 North America
13.1.1 North America Vaccines Market Overview
13.1.2 North America Vaccines Market Revenue and Forecasts to 2030
13.1.3 North America Vaccines Market Revenue and Forecasts and Analysis - By Type
13.1.4 North America Vaccines Market Revenue and Forecasts and Analysis - By Technology
13.1.5 North America Vaccines Market Revenue and Forecasts and Analysis - By Application
13.1.6 North America Vaccines Market Revenue and Forecasts and Analysis - By Route of Administration
13.1.7 North America Vaccines Market Revenue and Forecasts and Analysis - By Age
13.1.8 North America Vaccines Market Revenue and Forecasts and Analysis - By End User
13.1.9 North America Vaccines Market Revenue and Forecasts and Analysis - By Countries
13.1.9.1 United States Vaccines Market
13.1.9.1.1 United States Vaccines Market, by Type
13.1.9.1.2 United States Vaccines Market, by Technology
13.1.9.1.3 United States Vaccines Market, by Application
13.1.9.1.4 United States Vaccines Market, by Route of Administration
13.1.9.1.5 United States Vaccines Market, by Age
13.1.9.1.6 United States Vaccines Market, by End User
13.1.9.2 Canada Vaccines Market
13.1.9.2.1 Canada Vaccines Market, by Type
13.1.9.2.2 Canada Vaccines Market, by Technology
13.1.9.2.3 Canada Vaccines Market, by Application
13.1.9.2.4 Canada Vaccines Market, by Route of Administration
13.1.9.2.5 Canada Vaccines Market, by Age
13.1.9.2.6 Canada Vaccines Market, by End User
13.1.9.3 Mexico Vaccines Market
13.1.9.3.1 Mexico Vaccines Market, by Type
13.1.9.3.2 Mexico Vaccines Market, by Technology
13.1.9.3.3 Mexico Vaccines Market, by Application
13.1.9.3.4 Mexico Vaccines Market, by Route of Administration
13.1.9.3.5 Mexico Vaccines Market, by Age
13.1.9.3.6 Mexico Vaccines Market, by End User
Note - Similar analysis would be provided for below mentioned regions/countries
13.2 Europe
13.2.1 Germany
13.2.2 France
13.2.3 Italy
13.2.4 Spain
13.2.5 United Kingdom
13.2.6 Rest of Europe
13.3 Asia-Pacific
13.3.1 Australia
13.3.2 China
13.3.3 India
13.3.4 Japan
13.3.5 South Korea
13.3.6 Rest of Asia-Pacific
13.4 Middle East and Africa
13.4.1 South Africa
13.4.2 Saudi Arabia
13.4.3 U.A.E
13.4.4 Rest of Middle East and Africa
13.5 South and Central America
13.5.1 Brazil
13.5.2 Argentina
13.5.3 Rest of South and Central America
14. PRE AND POST COVID-19 IMPACT
15. INDUSTRY LANDSCAPE
15.1 Mergers and Acquisitions
15.2 Agreements, Collaborations, Joint Ventures
15.3 New Product Launches
15.4 Expansions and Other Strategic Developments
16. COMPETITIVE LANDSCAPE
16.1 Heat Map Analysis by Key Players
16.2 Company Positioning and Concentration
17. VACCINES MARKET - KEY COMPANY PROFILES
17.1 GSK
17.1.1 Key Facts
17.1.2 Business Description
17.1.3 Products and Services
17.1.4 Financial Overview
17.1.5 SWOT Analysis
17.1.6 Key Developments
Note - Similar information would be provided for below list of companies
17.2 Pfizer
17.3 Sanofi
17.4 Merck
17.5 Serum Institute of India (SII)
17.6 AstraZeneca
17.7 BioNTech
17.8 Biological E
17.9 Sinovac
17.10 Sinopharm
17.11 Bharat Biotech
18. APPENDIX
18.1 Glossary
18.2 About The Insight Partners
18.3 Market Intelligence Cloud
